4-Bromophenylhydrazinyl benzenesulfonylphenylureas as indoleamine 2,3-dioxygenase inhibitors with in vivo target inhibition and anti-tumor efficacy

Shu Yu Lin, Teng Kuang Yeh, Jen Shin Song, Ming Shiu Hung, Ming Fu Cheng, Fang Yu Liao, An Shiou Li, Shu Ying Cheng, Li Mei Lin, Chun Hsien Chiu, Mine Hsine Wu, Yi Jyun Lin, Wenchi Hsiao, Manwu Sun, Yi Hsin Wang, Chin Hsiang Huang, Ya Chu Tang, Hsin Huei Chang, Zih Ting Huang, Yu Sheng Chao & 5 others Chuan Shih, Shiow Lin Pan, Su Ying Wu, Ching Chuan Kuo, Shau Hua Ueng

Research output: Contribution to journalArticle

Abstract

Indoleamine 2,3-dioxygenase is a heme-containing enzyme implicated in the down regulation of the anti-tumor immune response, and considered a promising anti-cancer drug target. Several pharmaceutical companies, including Pfizer, Merck, and Bristol-Myers Squibb, are known to be in pursuit of IDO inhibitors, and Incyte recently reported good results in the phase II clinical trial of the IDO inhibitor Epacadostat. In previous work, we developed a series of IDO inhibitors based on a sulfonylhydrazide core structure, and explored how they could serve as potent IDO inhibitors with good drug profiles. Herein, we disclose the development of the 4-bromophenylhydrazinyl benzenesulfonylphenylurea 5k, a potent IDO inhibitor which demonstrated 25% tumor growth inhibition in a murine CT26 syngeneic model on day 18 with 100 mg/kg oral administration twice daily, and a 30% reduction in tumor weight. Pharmacodynamic testing of 5k found it to cause a 25% and 21% reduction in kyn/trp ratio at the plasma and tumor, respectively. In the CT26 tumor model, 5k was found to slightly increase the percentage of CD3+ T cells and lymphocyte responsiveness, indicating that 5k may have potential in modulating anti-tumor immunity. These data suggest 5k to be worthy of further investigation in the development of anti-tumor drugs.

LanguageEnglish
Pages600-607
Number of pages8
JournalBioorganic Chemistry
Volume77
DOIs
Publication statusPublished - Apr 1 2018

Fingerprint

Indoleamine-Pyrrole 2,3,-Dioxygenase
Tumors
Neoplasms
T-cells
Pharmaceutical Preparations
Pharmacodynamics
T-Lymphocytes
Phase II Clinical Trials
Tumor Burden
Heme
Oral Administration
Immunity
Down-Regulation
Plasmas
Testing
Enzymes
Growth

Keywords

  • 4-Bromophenylhydrazinyl benzenesulfonylphenylurea
  • Anti-tumor
  • In vivo target inhibition
  • Indoleamine 2,3-dioxygenase
  • Inhibitor
  • Kynurenine
  • Tryptophan

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Drug Discovery
  • Organic Chemistry

Cite this

4-Bromophenylhydrazinyl benzenesulfonylphenylureas as indoleamine 2,3-dioxygenase inhibitors with in vivo target inhibition and anti-tumor efficacy. / Lin, Shu Yu; Yeh, Teng Kuang; Song, Jen Shin; Hung, Ming Shiu; Cheng, Ming Fu; Liao, Fang Yu; Li, An Shiou; Cheng, Shu Ying; Lin, Li Mei; Chiu, Chun Hsien; Wu, Mine Hsine; Lin, Yi Jyun; Hsiao, Wenchi; Sun, Manwu; Wang, Yi Hsin; Huang, Chin Hsiang; Tang, Ya Chu; Chang, Hsin Huei; Huang, Zih Ting; Chao, Yu Sheng; Shih, Chuan; Pan, Shiow Lin; Wu, Su Ying; Kuo, Ching Chuan; Ueng, Shau Hua.

In: Bioorganic Chemistry, Vol. 77, 01.04.2018, p. 600-607.

Research output: Contribution to journalArticle

Lin, SY, Yeh, TK, Song, JS, Hung, MS, Cheng, MF, Liao, FY, Li, AS, Cheng, SY, Lin, LM, Chiu, CH, Wu, MH, Lin, YJ, Hsiao, W, Sun, M, Wang, YH, Huang, CH, Tang, YC, Chang, HH, Huang, ZT, Chao, YS, Shih, C, Pan, SL, Wu, SY, Kuo, CC & Ueng, SH 2018, '4-Bromophenylhydrazinyl benzenesulfonylphenylureas as indoleamine 2,3-dioxygenase inhibitors with in vivo target inhibition and anti-tumor efficacy' Bioorganic Chemistry, vol. 77, pp. 600-607. https://doi.org/10.1016/j.bioorg.2018.02.010
Lin, Shu Yu ; Yeh, Teng Kuang ; Song, Jen Shin ; Hung, Ming Shiu ; Cheng, Ming Fu ; Liao, Fang Yu ; Li, An Shiou ; Cheng, Shu Ying ; Lin, Li Mei ; Chiu, Chun Hsien ; Wu, Mine Hsine ; Lin, Yi Jyun ; Hsiao, Wenchi ; Sun, Manwu ; Wang, Yi Hsin ; Huang, Chin Hsiang ; Tang, Ya Chu ; Chang, Hsin Huei ; Huang, Zih Ting ; Chao, Yu Sheng ; Shih, Chuan ; Pan, Shiow Lin ; Wu, Su Ying ; Kuo, Ching Chuan ; Ueng, Shau Hua. / 4-Bromophenylhydrazinyl benzenesulfonylphenylureas as indoleamine 2,3-dioxygenase inhibitors with in vivo target inhibition and anti-tumor efficacy. In: Bioorganic Chemistry. 2018 ; Vol. 77. pp. 600-607.
@article{93ab8694c14b4c0086e304342abc5c1d,
title = "4-Bromophenylhydrazinyl benzenesulfonylphenylureas as indoleamine 2,3-dioxygenase inhibitors with in vivo target inhibition and anti-tumor efficacy",
abstract = "Indoleamine 2,3-dioxygenase is a heme-containing enzyme implicated in the down regulation of the anti-tumor immune response, and considered a promising anti-cancer drug target. Several pharmaceutical companies, including Pfizer, Merck, and Bristol-Myers Squibb, are known to be in pursuit of IDO inhibitors, and Incyte recently reported good results in the phase II clinical trial of the IDO inhibitor Epacadostat. In previous work, we developed a series of IDO inhibitors based on a sulfonylhydrazide core structure, and explored how they could serve as potent IDO inhibitors with good drug profiles. Herein, we disclose the development of the 4-bromophenylhydrazinyl benzenesulfonylphenylurea 5k, a potent IDO inhibitor which demonstrated 25{\%} tumor growth inhibition in a murine CT26 syngeneic model on day 18 with 100 mg/kg oral administration twice daily, and a 30{\%} reduction in tumor weight. Pharmacodynamic testing of 5k found it to cause a 25{\%} and 21{\%} reduction in kyn/trp ratio at the plasma and tumor, respectively. In the CT26 tumor model, 5k was found to slightly increase the percentage of CD3+ T cells and lymphocyte responsiveness, indicating that 5k may have potential in modulating anti-tumor immunity. These data suggest 5k to be worthy of further investigation in the development of anti-tumor drugs.",
keywords = "4-Bromophenylhydrazinyl benzenesulfonylphenylurea, Anti-tumor, In vivo target inhibition, Indoleamine 2,3-dioxygenase, Inhibitor, Kynurenine, Tryptophan",
author = "Lin, {Shu Yu} and Yeh, {Teng Kuang} and Song, {Jen Shin} and Hung, {Ming Shiu} and Cheng, {Ming Fu} and Liao, {Fang Yu} and Li, {An Shiou} and Cheng, {Shu Ying} and Lin, {Li Mei} and Chiu, {Chun Hsien} and Wu, {Mine Hsine} and Lin, {Yi Jyun} and Wenchi Hsiao and Manwu Sun and Wang, {Yi Hsin} and Huang, {Chin Hsiang} and Tang, {Ya Chu} and Chang, {Hsin Huei} and Huang, {Zih Ting} and Chao, {Yu Sheng} and Chuan Shih and Pan, {Shiow Lin} and Wu, {Su Ying} and Kuo, {Ching Chuan} and Ueng, {Shau Hua}",
year = "2018",
month = "4",
day = "1",
doi = "10.1016/j.bioorg.2018.02.010",
language = "English",
volume = "77",
pages = "600--607",
journal = "Bioorganic Chemistry",
issn = "0045-2068",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - 4-Bromophenylhydrazinyl benzenesulfonylphenylureas as indoleamine 2,3-dioxygenase inhibitors with in vivo target inhibition and anti-tumor efficacy

AU - Lin, Shu Yu

AU - Yeh, Teng Kuang

AU - Song, Jen Shin

AU - Hung, Ming Shiu

AU - Cheng, Ming Fu

AU - Liao, Fang Yu

AU - Li, An Shiou

AU - Cheng, Shu Ying

AU - Lin, Li Mei

AU - Chiu, Chun Hsien

AU - Wu, Mine Hsine

AU - Lin, Yi Jyun

AU - Hsiao, Wenchi

AU - Sun, Manwu

AU - Wang, Yi Hsin

AU - Huang, Chin Hsiang

AU - Tang, Ya Chu

AU - Chang, Hsin Huei

AU - Huang, Zih Ting

AU - Chao, Yu Sheng

AU - Shih, Chuan

AU - Pan, Shiow Lin

AU - Wu, Su Ying

AU - Kuo, Ching Chuan

AU - Ueng, Shau Hua

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Indoleamine 2,3-dioxygenase is a heme-containing enzyme implicated in the down regulation of the anti-tumor immune response, and considered a promising anti-cancer drug target. Several pharmaceutical companies, including Pfizer, Merck, and Bristol-Myers Squibb, are known to be in pursuit of IDO inhibitors, and Incyte recently reported good results in the phase II clinical trial of the IDO inhibitor Epacadostat. In previous work, we developed a series of IDO inhibitors based on a sulfonylhydrazide core structure, and explored how they could serve as potent IDO inhibitors with good drug profiles. Herein, we disclose the development of the 4-bromophenylhydrazinyl benzenesulfonylphenylurea 5k, a potent IDO inhibitor which demonstrated 25% tumor growth inhibition in a murine CT26 syngeneic model on day 18 with 100 mg/kg oral administration twice daily, and a 30% reduction in tumor weight. Pharmacodynamic testing of 5k found it to cause a 25% and 21% reduction in kyn/trp ratio at the plasma and tumor, respectively. In the CT26 tumor model, 5k was found to slightly increase the percentage of CD3+ T cells and lymphocyte responsiveness, indicating that 5k may have potential in modulating anti-tumor immunity. These data suggest 5k to be worthy of further investigation in the development of anti-tumor drugs.

AB - Indoleamine 2,3-dioxygenase is a heme-containing enzyme implicated in the down regulation of the anti-tumor immune response, and considered a promising anti-cancer drug target. Several pharmaceutical companies, including Pfizer, Merck, and Bristol-Myers Squibb, are known to be in pursuit of IDO inhibitors, and Incyte recently reported good results in the phase II clinical trial of the IDO inhibitor Epacadostat. In previous work, we developed a series of IDO inhibitors based on a sulfonylhydrazide core structure, and explored how they could serve as potent IDO inhibitors with good drug profiles. Herein, we disclose the development of the 4-bromophenylhydrazinyl benzenesulfonylphenylurea 5k, a potent IDO inhibitor which demonstrated 25% tumor growth inhibition in a murine CT26 syngeneic model on day 18 with 100 mg/kg oral administration twice daily, and a 30% reduction in tumor weight. Pharmacodynamic testing of 5k found it to cause a 25% and 21% reduction in kyn/trp ratio at the plasma and tumor, respectively. In the CT26 tumor model, 5k was found to slightly increase the percentage of CD3+ T cells and lymphocyte responsiveness, indicating that 5k may have potential in modulating anti-tumor immunity. These data suggest 5k to be worthy of further investigation in the development of anti-tumor drugs.

KW - 4-Bromophenylhydrazinyl benzenesulfonylphenylurea

KW - Anti-tumor

KW - In vivo target inhibition

KW - Indoleamine 2,3-dioxygenase

KW - Inhibitor

KW - Kynurenine

KW - Tryptophan

UR - http://www.scopus.com/inward/record.url?scp=85042508065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042508065&partnerID=8YFLogxK

U2 - 10.1016/j.bioorg.2018.02.010

DO - 10.1016/j.bioorg.2018.02.010

M3 - Article

VL - 77

SP - 600

EP - 607

JO - Bioorganic Chemistry

T2 - Bioorganic Chemistry

JF - Bioorganic Chemistry

SN - 0045-2068

ER -